Verastem Oncology, a biopharmaceutical company, announced the grant of stock options to purchase 45,000 shares of its common stock to four new employees. These stock options were granted under the Nasdaq inducement grant exception as part of the employees' compensation package upon joining the company. The stock options have an exercise price of $4.29 per share, based on the closing price on July 1, 2025. The vesting schedule for these options begins with twenty-five percent vesting on the one-year anniversary of the employee's hire date, with the remainder vesting quarterly over the next three years, contingent upon continued employment with Verastem Oncology.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.